China Resources Sanjiu Pharmaceutical Co. Overview
- Status
-
Public
- Employees
-
20,031
- Stock Symbol
-
000999
- Investments
-
7
- Share Price
-
$5.83
- (As of Monday Closing)
China Resources Sanjiu Pharmaceutical Co. General Information
Description
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.
Contact Information
Website
www.999.com.cnCorporate Office
- Longhua New Mission High-tech Park View
- Qing Road on the 1st
- Shenzhen, 518110
- China
Corporate Office
- Longhua New Mission High-tech Park View
- Qing Road on the 1st
- Shenzhen, 518110
- China
China Resources Sanjiu Pharmaceutical Co. Stock Performance
As of 17-Mar-2025, China Resources Sanjiu Pharmaceutical Co.’s stock price is $5.83. Its current market cap is $7.49B with 1.28B shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.83 | $5.79 | $5.10 - $7.46 | $7.49B | 1.28B | 8.38M | $0.37 |
China Resources Sanjiu Pharmaceutical Co. Financials Summary
As of 31-Dec-2024, China Resources Sanjiu Pharmaceutical Co. has a trailing 12-month revenue of $3.85B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 7,711,511 | 7,711,511 | 7,014,671 | 6,037,508 |
| Revenue | 3,848,758 | 3,848,758 | 3,496,733 | 2,684,587 |
| EBITDA | 752,705 | 752,705 | 638,202 | 510,139 |
| Net Income | 469,362 | 469,362 | 403,248 | 363,618 |
| Total Assets | 5,490,606 | 5,490,606 | 5,663,806 | 3,931,237 |
| Total Debt | 179,340 | 179,340 | 421,263 | 56,691 |
China Resources Sanjiu Pharmaceutical Co. Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
China Resources Sanjiu Pharmaceutical Co. Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
China Resources Sanjiu Pharmaceutical Co. Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
China Resources Sanjiu Pharmaceutical Co. Investments & Acquisitions (7)
China Resources Sanjiu Pharmaceutical Co.’s most recent deal was a Secondary Transaction - Private with Respirent Pharmaceuticals for . The deal was made on 04-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Respirent Pharmaceuticals | 04-Jan-2024 | Secondary Transaction - Private | Drug Discovery | ||
| Respirent Pharmaceuticals | 04-Jan-2024 | Later Stage VC | Drug Discovery | ||
| Yibao Tech | 09-Nov-2022 | Early Stage VC | Life and Health Insurance | ||
| Respirent Pharmaceuticals | 11-Jun-2020 | Later Stage VC | Drug Discovery | ||
| Shenghuo Pharmaceutical Group | 19-Sep-2016 | Merger/Acquisition | Pharmaceuticals |
China Resources Sanjiu Pharmaceutical Co. ESG
Risk Overview
Risk Rating
Updated February, 15, 2025
33.96 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 421
Rank
Percentile
China Resources Sanjiu Pharmaceutical Co. Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Shenghuo Pharmaceutical Group | Kunming, China | 1995 |
China Resources Sanjiu Pharmaceutical Co. FAQs
-
Where is China Resources Sanjiu Pharmaceutical Co. headquartered?
China Resources Sanjiu Pharmaceutical Co. is headquartered in Shenzhen, China.
-
What is the size of China Resources Sanjiu Pharmaceutical Co.?
China Resources Sanjiu Pharmaceutical Co. has 20,031 total employees.
-
What industry is China Resources Sanjiu Pharmaceutical Co. in?
China Resources Sanjiu Pharmaceutical Co.’s primary industry is Pharmaceuticals.
-
Is China Resources Sanjiu Pharmaceutical Co. a private or public company?
China Resources Sanjiu Pharmaceutical Co. is a Public company.
-
What is China Resources Sanjiu Pharmaceutical Co.’s stock symbol?
The ticker symbol for China Resources Sanjiu Pharmaceutical Co. is 000999.
-
What is the current stock price of China Resources Sanjiu Pharmaceutical Co.?
As of 17-Mar-2025 the stock price of China Resources Sanjiu Pharmaceutical Co. is $5.83.
-
What is the current market cap of China Resources Sanjiu Pharmaceutical Co.?
The current market capitalization of China Resources Sanjiu Pharmaceutical Co. is $7.49B.
-
What is China Resources Sanjiu Pharmaceutical Co.’s current revenue?
The trailing twelve month revenue for China Resources Sanjiu Pharmaceutical Co. is $3.85B.
-
What is China Resources Sanjiu Pharmaceutical Co.’s annual earnings per share (EPS)?
China Resources Sanjiu Pharmaceutical Co.’s EPS for 12 months was $0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
